Efficacy and safety of dexmedetomidine in sepsis patients requiring mechanical ventilation: a systematic review and meta-analysis
| Autor: | Pinhu Liao, Zhao Liu, Bihui Yang, Yiqian Zeng |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Pharmacology
Mechanical ventilation business.industry medicine.medical_treatment Mortality rate Cochrane Library Length of Stay medicine.disease Intensive care unit Respiration Artificial law.invention Sepsis Intensive Care Units Randomized controlled trial law Relative risk Anesthesia medicine Humans Pharmacology (medical) Dexmedetomidine business medicine.drug |
| Zdroj: | Journal of clinical pharmacy and therapeuticsREFERENCES. 47(3) |
| ISSN: | 1365-2710 |
| Popis: | WHAT IS KNOWN AND OBJECTIVE Currently, dexmedetomidine is widely used in the treatment of sepsis patients requiring mechanical ventilation; however, its role remains controversial. The aim of this study was to assess the efficacy and safety of dexmedetomidine in sepsis patients requiring mechanical ventilation. METHODS The PubMed, Embase and Cochrane Library electronic databases were searched to identify relevant studies; Review Manager version 5.4 was used to perform the meta-analysis. Primary outcomes included the all-cause mortality rate at the longest follow-up available and the duration of mechanical ventilation. Secondary outcomes included length of intensive care unit (ICU) stay, length of hospital stay, and adverse events (bradycardia). RESULTS Five randomized controlled trials (RCTs), including 926 patients, were assessed. Overall, dexmedetomidine did not reduce all-cause mortality in mechanically ventilated patients with sepsis (relative risk [RR]: 0.9, 95% confidence interval [CI]: 0.77 to 1.05, p = 0.18, I2 = 37%). However, dexmedetomidine was associated with decreases in the length of hospital stay (mean difference [MD]: -2.99, 95% CI: -4.72 to -1.26, p = 0.0007, I2 = 0%), ICU length of stay (MD: -1.15, 95% CI: -2.06 to -0.24, p = 0.01, I2 = 32%) and duration of mechanical ventilation (MD: -0.72, 95% CI: -1.38 to -0.07, p = 0.03, I2 = 20%). However, dexmedetomidine increased the risk for bradycardia (22% versus 12.6%, respectively; RR: 1.73, 95% CI: 1.24 to 2.41, p = 0.001, I2 = 0%). WHAT IS NEW AND CONCLUSION Results suggested that dexmedetomidine did not reduce all-cause mortality in mechanically ventilated patients with sepsis. However, it was associated with decreases in length of hospital stay, ICU length of stay and duration of mechanical ventilation, although it increased the risk for bradycardia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|